U.K. Is First Country to Approve Moderna Omicron-Targeted Vaccine

Updated vaccine expected to have 'important role' in protecting people from COVID-19 this winter

covid vaccine
Adobe Stock

MONDAY, Aug. 15, 2022 (HealthDay News) -- A COVID-19 booster that is targeted to the omicron variant will be available soon -- and it has already been approved in Britain.

The U.K. Medicines and Healthcare Regulatory Agency was the first to give the go-ahead for the vaccine that was designed to fight both the original COVID-19 virus from 2020 and the omicron BA.1 variant, which began spreading last November, the Associated Press reported.

Health officials in the United Kingdom have not decided whether the vaccine is part of its fall COVID-19 strategy, though British officials have said everyone aged 50 years and older will be able to get a fall booster shot.

This vaccine's side effects are said to be typically "mild and self-resolving," similar to the earlier Moderna booster. This update will have an "important role" in protecting people from COVID-19 this winter, Stephane Bancel, Moderna chief executive, said in a company statement.

Having a targeted booster is a similar approach to what public health officials have done in years past with influenza, with an adjusted vaccine that targets up to four strains of the flu. About 70 percent of most recent COVID-19 virus samples collected arise from the omicron subvariant BA.5, according to the World Health Organization.

Other countries may follow Britain, including the United States. The U.S. Food and Drug Administration said in June that updated boosters needed to have protection against omicron variants, the AP reported. In Germany, the health minister said on Friday that the European Medicines Agency may clear the new vaccine in September.

Associated Press Article

Physician’s Briefing Staff

Updated on September 21, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ